Bacterial Vaccine Targets
A recent publication [1] from the team which brought us the Meningococcal B vaccine is of interest from the perspective of vaccine development strategy and feasibility.
Tag Archives: Novartis
Fighting P. aeruginosa (Part II)
At a still earlier stage of development, we found some exciting anti-pseudomonal compounds. First, there is BAL-30072, a sulfactam-derivative. It has an interesting dual MoA as it works not only as a traditional B-lactam but also as an Fe-chelator blocking bacteria from accessing this essential nutrient [i]. It has very good anti-pseudomonas Continue reading Fighting P. aeruginosa (Part II)
Fighting P. aeruginosa (Part I)
It has never been easy to cure Pseudomonas aeruginosa infections. Few antibiotics nowadays have reliable activity against this problem pathogen that seems to have more built-in resistance features than most other Gram-negatives. In the past, cephalosporins, aztreonam, penems, ciprofloxacin, and aminoglycosides were useful drugs with reliably cidal activity, especially when Continue reading Fighting P. aeruginosa (Part I)